Abbott Diagnostics Looking Beyond FDA Consent Decree In 2002
This article was originally published in The Gray Sheet
Executive Summary
Abbott Labs is forecasting diagnostics sales growth in the "mid to high single-digit" range in 2002, with the final resolution of its consent decree with FDA and a series of planned product launches, including Prism high-throughput automated blood screening system assays
You may also be interested in...
Abbott Consent Decree Costs Escalate With Failed FDA QSR Inspection
Costs related to Abbott's FDA consent decree could approach $1 bil. in lost revenue alone following a failed follow-up inspection of the company's Lake County, Illinois diagnostic manufacturing operations
Abbott Consent Decree Costs Escalate With Failed FDA QSR Inspection
Costs related to Abbott's FDA consent decree could approach $1 bil. in lost revenue alone following a failed follow-up inspection of the company's Lake County, Illinois diagnostic manufacturing operations
Abbott Expands Commitment To Vascular Device Biz Through Biocompatibles
Abbott's acquisition of Biocompatibles' stent business, unveiled March 18, reflects an expanded commitment by Abbott to its vascular medicine franchise - particularly focusing on high growth market segments like stents, vessel closure and embolic protection